Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Jaypirca
Pharma
BeOne's Venclexta challenger Beqalzi nets FDA approval
MCL is BeOne’s stepping stone to potentially reshape the broader BCL-2 landscape, which is presently dominated by AbbVie and Roche’s Venclexta.
Angus Liu
May 13, 2026 4:45pm
Why Lilly is betting on 2nd-line CLL despite 1st-line wins
Dec 9, 2025 7:30am
Lilly's BTK inhibitor Jaypirca wins lymphoma label expansion
Dec 3, 2025 8:25am
Trial results show value of Lilly's Jaypirca in front-line CLL
Sep 8, 2025 11:37am
BeOne widens BTK lead over AstraZeneca
Aug 6, 2025 10:55am
Lilly's BTK Jaypirca makes the grade versus Imbruvica
Jul 29, 2025 4:56pm
